{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:14:48Z","timestamp":1794874488829,"version":"4.9.1"},"reference-count":155,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T00:00:00Z","timestamp":1495584000000},"content-version":"vor","delay-in-days":388,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.jacc.2016.02.071","type":"journal-article","created":{"date-parts":[[2016,5,16]],"date-time":"2016-05-16T14:15:36Z","timestamp":1463408136000},"page":"2395-2410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":663,"title":["Statin-Associated Side Effects"],"prefix":"10.1016","volume":"67","author":[{"given":"Paul D.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Panza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Zaleski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2016.02.071_bib1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2016.02.071_bib2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2016.02.071_bib3","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","article-title":"Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences","volume":"34","author":"Chowdhury","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2016.02.071_bib4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"40","author":"Pasternak","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib5","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cjca.2013.09.023","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update","volume":"29","author":"Mancini","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib6","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2016.02.071_bib7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2016.02.071_bib8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJM198801073180110","article-title":"Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin","volume":"318","author":"Norman","year":"1988","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib9","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2016.02.071_bib10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacl.2015.01.004","article-title":"Changes in muscle strength in individuals with statin-induced myopathy: a summary of 3 investigations","volume":"9","author":"Panza","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2016.02.071_bib11","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/ki.1990.263","article-title":"Catastrophic medical events with exhaustive exercise: \u201cwhite collar rhabdomyolysis\u201d","volume":"38","author":"Knochel","year":"1990","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2016.02.071_bib12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.02.071_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A\u00a0randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","author":"Taylor","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2016.02.071_bib14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.amjmed.2011.08.007","article-title":"Statin use and musculoskeletal pain among adults with and without arthritis","volume":"125","author":"Buettner","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","article-title":"A\u00a0systematic review of statin-induced muscle problems in clinical trials","volume":"168","author":"Ganga","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2016.02.071_bib16","first-page":"275","article-title":"Creatine kinase elevations in marathon runners: relationship to training and competition","volume":"53","author":"Siegel","year":"1980","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1249\/01.mss.0000210192.49210.fc","article-title":"Serum creatine kinase levels and renal function measures in exertional muscle damage","volume":"38","author":"Clarkson","year":"2006","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.jacc.2016.02.071_bib18","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","article-title":"Lovastatin increases exercise-induced skeletal muscle injury","volume":"46","author":"Thompson","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.jacc.2016.02.071_bib19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","article-title":"Effect of statins on creatine kinase levels before and after a marathon run","volume":"109","author":"Parker","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/pds.1895","article-title":"Muscle toxicity with statins","volume":"19","author":"Hedenmalm","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jacc.2016.02.071_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jclinepi.2004.10.004","article-title":"Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis","volume":"58","author":"Andrade","year":"2005","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jacl.2012.06.006","article-title":"Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting","volume":"7","author":"Cziraky","year":"2013","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2016.02.071_bib23","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/pds.1287","article-title":"Risk factors for statin-associated rhabdomyolysis","volume":"16","author":"Schech","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jacc.2016.02.071_bib24","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1517\/14740338.2015.1039980","article-title":"Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"14","author":"Banach","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jacc.2016.02.071_bib25","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1517\/14740338.2012.712959","article-title":"Statin drug interactions and related adverse reactions","volume":"11","author":"Bellosta","year":"2012","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jacc.2016.02.071_bib26","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1021\/tx700079z","article-title":"Cytochrome P450 and chemical toxicology","volume":"21","author":"Guengerich","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.jacc.2016.02.071_bib27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.amjcard.2006.03.057","article-title":"Rhabdomyolysis associated with pomegranate juice consumption","volume":"98","author":"Sorokin","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib28","unstructured":"Livalo [package insert]. Montgomery AL: Kowa Pharmaceuticals America, Inc.,\u00a02012."},{"key":"10.1016\/j.jacc.2016.02.071_bib29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2125.1998.00764.x","article-title":"Grapefruit juice-drug interactions","volume":"46","author":"Bailey","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2016.02.071_bib30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study","volume":"359","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib31","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/gim.2014.41","article-title":"Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review","volume":"16","author":"Canestaro","year":"2014","journal-title":"Genet Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/CIRCRESAHA.109.203596","article-title":"Human skeletal muscle drug transporters determine local exposure and toxicity of statins","volume":"106","author":"Knauer","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2016.02.071_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0009-9236(97)90034-5","article-title":"Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses","volume":"62","author":"Olbricht","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2016.02.071_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1034\/j.1600-0773.2001.d01-147.x","article-title":"Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin)","volume":"89","author":"Bramow","year":"2001","journal-title":"Pharmacol Toxicol"},{"key":"10.1016\/j.jacc.2016.02.071_bib35","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1124\/jpet.301.3.1042","article-title":"Mechanistic studies on metabolic interactions between gemfibrozil and statins","volume":"301","author":"Prueksaritanont","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jacc.2016.02.071_bib36","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1124\/dmd.30.5.505","article-title":"Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.jacc.2016.02.071_bib37","unstructured":"FDA: Limit use of 80 mg Simvastatin. FDA Consumer Health Information, June 2011. U.S. Food and Drug Administration. 2011. Available at: http:\/\/www.fda.gov\/downloads\/ForConsumers\/ConsumerUpdates\/UCM257911. Accessed March 12,\u00a02016."},{"key":"10.1016\/j.jacc.2016.02.071_bib38","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed\u00a0conservative simvastatin strategy in patients with acute coronary syndromes: phase\u00a0Z\u00a0of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2016.02.071_bib39","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.02.071_bib40","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2016.02.071_bib41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jacc.2016.02.071_bib42","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jacc.2016.02.071_bib43","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.23854","article-title":"Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies","volume":"48","author":"Mohassel","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jacc.2016.02.071_bib44","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2014.10.118","article-title":"Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients","volume":"178","author":"Michalska-Kasiczak","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib45","first-page":"86","article-title":"Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation","volume":"7","author":"Khayznikov","year":"2015","journal-title":"N\u00a0Am J Med Sci"},{"key":"10.1016\/j.jacc.2016.02.071_bib46","first-page":"1047","article-title":"P5981: Futility of supplementation with Coenzyme Q10 for statin-induced myopathy: an updated (2015) meta-analysis of randomized controlled trials","volume":"36","author":"Banach","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2016.02.071_bib47","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","article-title":"Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study","volume":"37","author":"Nielsen","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2016.02.071_bib48","unstructured":"Nocebo. Wikipedia, The Free Encyclopedia. 2016. Available at: https:\/\/en.wikipedia.org\/wiki\/Nocebo. Accessed March 12,\u00a02016."},{"key":"10.1016\/j.jacc.2016.02.071_bib49","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.0197-3118.2005.04404.x","article-title":"Decreasing LDL cholesterol and medication cost with every-other-day statin therapy","volume":"8","author":"Juszczyk","year":"2005","journal-title":"Prev Cardiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib51","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1345\/aph.1R509","article-title":"Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy","volume":"47","author":"Keating","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacc.2016.02.071_bib52","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.amjcard.2008.02.061","article-title":"Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins","volume":"101","author":"Gadarla","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib53","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib54","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib55","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib56","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.amjcard.2006.08.051","article-title":"Safety and efficacy of statins in Asians","volume":"99","author":"Liao","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2016.02.071_bib58","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib59","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib60","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1096\/fj.08-128843","article-title":"Statin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defect","volume":"23","author":"Cao","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.jacc.2016.02.071_bib61","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.jacc.2016.02.071_bib62","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clpt.2005.03.006","article-title":"High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial","volume":"78","author":"P\u00e4iv\u00e4","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacc.2016.02.071_bib63","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib64","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nm0604-584","article-title":"Balancing muscle hypertrophy and atrophy","volume":"10","author":"Hoffman","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib65","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1113\/jphysiol.2008.164699","article-title":"Blunted Akt\/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy","volume":"587","author":"Mallinson","year":"2009","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib66","first-page":"3940","article-title":"The muscle-specific ubiquitin ligase atrogin-1\/MAFbx mediates statin-induced muscle toxicity","volume":"117","author":"Hanai","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2016.02.071_bib67","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1161\/01.ATV.0000190608.28704.71","article-title":"Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins","volume":"25","author":"Urso","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2016.02.071_bib68","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1113\/jphysiol.2014.285577","article-title":"Statin myalgia is not associated with reduced muscle strength, mass or protein turnover in older male volunteers, but is allied with a slowing of time to peak power output, insulin resistance and differential muscle mRNA expression","volume":"593","author":"Mallinson","year":"2015","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib69","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jacc.2013.03.030","article-title":"Statins, exercise, and exercise training","volume":"62","author":"Thompson","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib70","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2217\/14622416.9.8.1133","article-title":"Molecular basis for statin-induced muscle toxicity: implications and possibilities","volume":"9","author":"Buettner","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jacc.2016.02.071_bib71","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jacc.2013.02.074","article-title":"Simvastatin impairs exercise training adaptations","volume":"62","author":"Mikus","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib72","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jacc.2012.09.036","article-title":"Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance","volume":"61","author":"Larsen","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib73","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1254\/jphs.08238FP","article-title":"Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats","volume":"109","author":"Itagaki","year":"2009","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jacc.2016.02.071_bib74","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.103.3.357","article-title":"Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study","volume":"103","author":"Freeman","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.02.071_bib75","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib76","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/01.ATV.19.4.972","article-title":"C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?","volume":"19","author":"Yudkin","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2016.02.071_bib77","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"Swerdlow","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.02.071_bib78","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2016.02.071_bib79","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.02.071_bib80","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCULATIONAHA.109.906479","volume":"121","author":"Mora","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.02.071_bib81","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.02.071_bib82","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/archinternmed.2011.625","article-title":"Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative","volume":"172","author":"Culver","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib83","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2016.02.071_bib84","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jama.2015.1206","article-title":"Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus","volume":"313","author":"Besseling","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2016.02.071_bib85","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1210\/en.2008-0161","article-title":"Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic \u03b2-cells","volume":"149","author":"Xia","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.jacc.2016.02.071_bib86","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.tem.2012.06.004","article-title":"Mitochondrial dysfunction in white adipose tissue","volume":"23","author":"Kusminski","year":"2012","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jacc.2016.02.071_bib87","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.tem.2012.06.002","article-title":"Mitochondrial dysfunction in pancreatic \u03b2 cells","volume":"23","author":"Supale","year":"2012","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jacc.2016.02.071_bib88","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00125-006-0269-5","article-title":"Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control","volume":"49","author":"Nakata","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2016.02.071_bib89","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0014-5793(01)03007-1","article-title":"Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes","volume":"507","author":"Chamberlain","year":"2001","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jacc.2016.02.071_bib90","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3233\/JAD-140954","article-title":"Midlife vascular risk factors and the risk of Alzheimer's disease: a systematic review and meta-analysis","volume":"42","author":"Meng","year":"2014","journal-title":"J\u00a0Alzheimers Dis"},{"key":"10.1016\/j.jacc.2016.02.071_bib91","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1592\/phco.23.7.871.32720","article-title":"Statin-associated memory loss: analysis of 60 case reports and review of the literature","volume":"23","author":"Wagstaff","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacc.2016.02.071_bib92","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1249\/00003677-199101000-00003","article-title":"The metabolic effects of exercise-induced muscle damage","volume":"19","author":"Evans","year":"1991","journal-title":"Exerc Sport Sci Rev"},{"key":"10.1016\/j.jacc.2016.02.071_bib93","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9343(00)00353-3","article-title":"Effects of lovastatin on cognitive function and psychological well-being","volume":"108","author":"Muldoon","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib94","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjmed.2004.07.041","article-title":"Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults","volume":"117","author":"Muldoon","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib95","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archneur.59.3.378","article-title":"Serum lipoprotein levels, statin use, and cognitive function in older women","volume":"59","author":"Yaffe","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jacc.2016.02.071_bib96","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1212\/01.wnl.0000182897.18229.ec","article-title":"Statins and cognitive function in the elderly: the Cardiovascular Health Study","volume":"65","author":"Bernick","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2016.02.071_bib97","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1592\/phco.23.6.726.32184","article-title":"The role of lipid-lowering drugs in cognitive function: a meta-analysis of observational studies","volume":"23","author":"Etminan","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacc.2016.02.071_bib98","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/01.WNL.0000160114.42643.31","article-title":"APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study","volume":"64","author":"Dufouil","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2016.02.071_bib99","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2174\/156720508785132316","article-title":"Reduced risk of incident AD with elective statin use in a clinical trial cohort","volume":"5","author":"Sparks","year":"2008","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.jacc.2016.02.071_bib100","doi-asserted-by":"crossref","first-page":"M414","DOI":"10.1093\/gerona\/57.7.M414","article-title":"The\u00a0impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment","volume":"57","author":"Hajjar","year":"2002","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jacc.2016.02.071_bib101","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0404.2006.00690.x","article-title":"Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial","volume":"185","author":"Sparks","year":"2006","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.jacc.2016.02.071_bib102","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1212\/01.WNL.0000142963.90204.58","article-title":"Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study","volume":"63","author":"Li","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2016.02.071_bib103","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1212\/01.wnl.0000288181.00826.63","article-title":"Statins, incident Alzheimer disease, change in cognitive function, and neuropathology","volume":"70","author":"Arvanitakis","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2016.02.071_bib104","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/archpsyc.62.2.217","article-title":"Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study","volume":"62","author":"Zandi","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jacc.2016.02.071_bib105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1365-2125.1995.tb04458.x","article-title":"Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia","volume":"39","author":"Cutler","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2016.02.071_bib106","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1212\/01.wnl.0000279333.77404.d7","article-title":"Association of statin use with cognitive decline in elderly African Americans","volume":"69","author":"Szwast","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2016.02.071_bib107","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1532-5415.2007.01071.x","article-title":"Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults","volume":"55","author":"Agostini","year":"2007","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.jacc.2016.02.071_bib108","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2016.02.071_bib109","first-page":"CD007514","article-title":"Statins for the treatment of dementia","volume":"7","author":"McGuinness","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2016.02.071_bib110","first-page":"85","article-title":"Pravastatin and cognitive function in the elderly. Results of the PROSPER study","volume":"257","author":"Trompet","year":"2010","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.jacc.2016.02.071_bib111","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.mayocp.2013.07.013","article-title":"Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects","volume":"88","author":"Swiger","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2016.02.071_bib112","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11606-014-3115-3","article-title":"Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Ott","year":"2015","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib113","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jacl.2014.02.013","article-title":"An assessment by the Statin Cognitive Safety Task Force: 2014 update","volume":"8","author":"Rojas-Fernandez","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2016.02.071_bib114","first-page":"21","article-title":"Statin label changes","volume":"54","year":"2012","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.jacc.2016.02.071_bib115","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1017\/S1355617703960061","article-title":"Examining the range of normal intraindividual variability in neuropsychological test performance","volume":"9","author":"Schretlen","year":"2003","journal-title":"J\u00a0Int Neuropsychol Soc"},{"key":"10.1016\/j.jacc.2016.02.071_bib116","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/153331750401900506","article-title":"Statin use and hippocampal volumes in elderly subjects at risk for Alzheimer's disease: a pilot observational study","volume":"19","author":"Doraiswamy","year":"2004","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"Suppl 2","key":"10.1016\/j.jacc.2016.02.071_bib117","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.3949\/ccjm.75.Suppl_2.S87","article-title":"Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial","volume":"75","author":"Sparks","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib118","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1194\/jlr.R400004-JLR200","article-title":"Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal","volume":"45","author":"Dietschy","year":"2004","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2016.02.071_bib119","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/archneur.59.2.213","article-title":"Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain","volume":"59","author":"Locatelli","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jacc.2016.02.071_bib120","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ana.10292","article-title":"Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial","volume":"52","author":"Simons","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jacc.2016.02.071_bib121","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00228-005-0068-9","article-title":"Effect of pravastatin on plasma sterols and oxysterols in men","volume":"62","author":"Thelen","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2016.02.071_bib122","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/0091270006289851","article-title":"High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels","volume":"46","author":"Thelen","year":"2006","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jacc.2016.02.071_bib123","doi-asserted-by":"crossref","first-page":"20607","DOI":"10.3390\/ijms151120607","article-title":"Molecular mechanisms underlying the effects of statins in the central nervous system","volume":"15","author":"McFarland","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacc.2016.02.071_bib124","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1592\/phco.24.6.584.34738","article-title":"Statins and liver toxicity: a meta-analysis","volume":"24","author":"de Denus","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacc.2016.02.071_bib125","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4065\/mcp.2009.0365","article-title":"Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma","volume":"85","author":"Calderon","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2016.02.071_bib126","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jacl.2014.02.011","article-title":"An assessment by the Statin Liver Safety Task Force: 2014 update","volume":"8","author":"Bays","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2016.02.071_bib127","doi-asserted-by":"crossref","first-page":"f880","DOI":"10.1136\/bmj.f880","article-title":"Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases","volume":"346","author":"Dormuth","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2016.02.071_bib128","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.amjcard.2014.03.046","article-title":"Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials","volume":"113","author":"Bangalore","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib129","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","article-title":"Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2016.02.071_bib130","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1016\/j.ijcard.2012.05.010","article-title":"Effects\u00a0of atorvastatin and rosuvastatin on renal function: a meta-analysis","volume":"167","author":"Savarese","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib131","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.amjcard.2007.02.068","article-title":"Tendon rupture associated with simvastatin\/ezetimibe therapy","volume":"100","author":"Pullatt","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2016.02.071_bib132","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MJT.0000000000000039","article-title":"Is statin use associated with tendon rupture? A population-based retrospective cohort analysis","volume":"22","author":"Contractor","year":"2015","journal-title":"Am J Ther"},{"key":"10.1016\/j.jacc.2016.02.071_bib133","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/01.STR.15.2.244","article-title":"Predictors of stroke-associated mortality in the elderly","volume":"15","author":"Khaw","year":"1984","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2016.02.071_bib134","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM198904063201405","article-title":"Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial","volume":"320","author":"Iso","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib135","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/01.STR.20.11.1460","article-title":"Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program","volume":"20","author":"Yano","year":"1989","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2016.02.071_bib136","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1161\/STROKEAHA.113.001326","article-title":"Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis","volume":"44","author":"Wang","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2016.02.071_bib137","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(04)15690-0","article-title":"Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions","volume":"363","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2016.02.071_bib138","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib139","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1445-5994.1995.tb02870.x","article-title":"Dermatomyositis with lung involvement in a patient treated with simvastatin","volume":"25","author":"Hill","year":"1995","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib140","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1378\/chest.08-0943","article-title":"Statins and interstitial lung disease: a systematic review of the literature and of Food and Drug Administration adverse event reports","volume":"134","author":"Fern\u00e1ndez","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2016.02.071_bib141","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMcpc1415200","article-title":"Case records of the Massachusetts General Hospital. Case 14\u20132015. A 58-year-old woman with shortness of breath","volume":"372","author":"Shea","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib142","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4046\/trd.2015.78.3.281","article-title":"A\u00a0case of statin-induced interstitial pneumonitis due to rosuvastatin","volume":"78","author":"Kim","year":"2015","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"10.1016\/j.jacc.2016.02.071_bib143","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/thoraxjnl-2012-201823","article-title":"Statins and the risk of interstitial lung disease: a cohort study","volume":"68","author":"Saad","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.jacc.2016.02.071_bib144","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.rmed.2009.01.004","article-title":"Association between ischaemic heart disease and interstitial lung disease: a case-control study","volume":"103","author":"Ponnuswamy","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib145","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1164\/rccm.201108-1574OC","article-title":"Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation","volume":"185","author":"Xu","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib146","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1183\/09031936.02.00258802","article-title":"Statin-induced fibrotic nonspecific interstitial pneumonia","volume":"19","author":"Lantuejoul","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2016.02.071_bib147","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.4049\/jimmunol.176.9.5284","article-title":"Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes","volume":"176","author":"Coward","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jacc.2016.02.071_bib148","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1741-7015-11-57","article-title":"The effect of statins on testosterone in men\u00a0and women, a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Schooling","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib149","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/gps.666","article-title":"Serum cholesterol and depressive symptoms in elderly Finnish men","volume":"17","author":"Aij\u00e4nsepp\u00e4","year":"2002","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1016\/j.jacc.2016.02.071_bib150","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10865-012-9409-1","article-title":"Depressive symptoms and serum lipid levels in young adult women","volume":"36","author":"Fang","year":"2013","journal-title":"J\u00a0Behav Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib151","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2006.08.069","article-title":"Cholesterol depletion reduces serotonin binding and signaling via human 5-HT7(a) receptors","volume":"552","author":"Sj\u00f6gren","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jacc.2016.02.071_bib152","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1517\/14656566.2013.803067","article-title":"The relationship between statins and depression: a review of the literature","volume":"14","author":"You","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jacc.2016.02.071_bib153","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1741-7015-10-154","article-title":"The impact of statins on psychological wellbeing: a systematic review and meta-analysis","volume":"10","author":"O'Neil","year":"2012","journal-title":"BMC Med"},{"key":"10.1016\/j.jacc.2016.02.071_bib154","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40264-014-0163-x","article-title":"Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database","volume":"37","author":"Takada","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.jacc.2016.02.071_bib155","first-page":"915","article-title":"Sleep changes following statin therapy: a systematic review and meta-analysis of randomized placebo-controlled polysomnographic trials","volume":"11","author":"Broncel","year":"2015","journal-title":"Arch Med Sci"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109716016922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109716016922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T02:45:29Z","timestamp":1656729929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109716016922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":155,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0735109716016922"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2016.02.071","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin-Associated Side Effects","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2016.02.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}